Endocyte falls as vintafolide monotherapy unlikely to show NSCLC PFS superiority

|By:, SA News Editor

Endocyte (ECYT) plummets as the DSMB for TARGET advises investigators and patients that vintafolide monotherapy is not likely to be declared superior in PFS to docetaxel.

The Phase 2b trial had two arms, vintafolide monotherapy and vintafolide in combination with docetaxel, which were to be compared with standard of care (docetaxel monotherapy).

The DSMB did recommend the continuation of the combination therapy arm.

Top-line results are due early next year. (PR)

ECYT -27.4% premarket